Xstrahl to feature Radiant™ Aura at ASTRO 2023 to expand office-based radiation therapy treatment options for patients with non-melanoma skin cancers and keloid scarring
Xstrahl will also showcase the Xstrahl 200 orthovoltage system for superficial skin treatments, selective benign conditions, and palliative care
Radiant Aura is the only dual modality surface radiation therapy system that enables you to choose either electronic brachytherapy or SRT based on the needs of your patients.
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura, a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting in San Diego, CA, October 1-3, 2023, booth #2216.
“We are thrilled that Radiant Aura is now commercially available to support the delivery of office-based radiation therapy for patients with NMSC when surgery is not possible, contraindicated, or simply not preferred due to cosmetic concerns,” said Adrian Treverton, CEO of Xstrahl.
Radiant Aura is the only dual modality system that offers both non-invasive electronic brachytherapy (eBt) and superficial radiation therapy (SRT) for NMSC and keloid scarring. The device received U.S. Food and Drug Administration (FDA) 510(k) clearance in July 2023.
In addition to Radiant Aura, ASTRO attendees will also be able to demonstrate Xstrahl 200, a versatile orthovoltage radiotherapy solution for treating superficial lesions, skin cancers, and benign conditions and also for delivering palliative care.
“The Xstrahl 200 is a great addition to a linac-based cancer therapy program because it helps improve the level of patient care, treatment capacity, and the range of treatment options for patients quickly, simply, and affordably. It provides excellent maneuverability to help support the delivery of low-energy radiation treatments all over the body, which is especially important for patients with mobility issues,” Treverton added.
As the founding sponsor of The International Organisation for Radiotherapy for Benign Conditions (IORBC), Xstrahl also invites all ASTRO attendees to visit booth #2216 to learn more about this international clinical network to increase awareness of the treatment of benign conditions with radiotherapy. Membership is complimentary and provides access to up-to-date research data, protocols, and best practices as well as other educational events.
In addition to its clinical radiation therapy systems, Xstrahl will also showcase the new CIX1 cabinet irradiator, a powerful benchtop radiation delivery device designed for radiation research. CIX1 is designed to make radiation accessible to every research lab and facilitate the safe and accurate irradiation of biological samples within a standard laboratory environment. By helping to support the realization of bench science to effective clinical applications, Xstrahl inspires science and advances care.
Visit Xstrahl at booth #2216 at ASTRO 2023, in San Diego, October 1-3, 2023.
About Xstrahl
Xstrahl is a medical technology company that designs radiation delivery devices to support clinical teams and cancer researchers. For more than 25 years, Xstrahl has been shaping the development of superficial and orthovoltage radiation therapy and advancing preclinical radiation research. Xstrahl systems are in operation at more than 700 treatment and research facilities worldwide.
To learn more about Radiant Aura, visit www.radiant-therapy.com
To learn more about all Xstrahl clinical and research systems, visit www.xstrahl.com
